Latest news with #EOP
Yahoo
5 days ago
- Business
- Yahoo
SRNS awards surpass $1 Million in Mini Grants for local STEM education
AIKEN, S.C. (WJBF) – Savannah River Nuclear Solutions' (SRNS) Education Outreach Programs (EOP) celebrated surpassing $1 million in Mini Grants for local STEM education this month. Since the initiative began in 2009, thousands of dollars have been awarded to educators from 4K through 12th grade across public, private and charter schools. This year, 110 educators received a total of $75,000 at a special reception at Newberry Hall in Aiken on May 15. According to SRNS, nearly 25,000 students across 74 schools will benefit from the Mini Grants, which provide $500, $750, or $1,000 to purchase STEM equipment, materials and supplies to enhance classroom instruction. 'Winning a Mini Grant for the third year in a row is a tremendous support for our science program,' said Joseph Cordova, Richmond County Copeland Elementary Educator. 'Last year, we used the funds to create a mobile science cart with essential science materials since we lack dedicated science classrooms. This year, the funds will support our fifth graders' Exhibition projects, bringing their prototypes to life with a 3D printer, which otherwise wouldn't be possible.' The winners are chosen based on their anonymously reviewed project proposals by a panel of 50 judges. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
14-05-2025
- Business
- Yahoo
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. Key Findings: Primary feasibility goal surpassed – 95 percent of participants (19/20) completed at least 75 percent of planned dosing, far exceeding the predefined 75 percent threshold. Early anti‑proliferative activity – Median Ki‑67 fell from 10.5 percent at baseline to 5 percent by Week 3 (prior to ovarian suppression); 65 percent of patients achieved Ki‑67 ≤ 10 percent at that time point, and suppression was maintained at surgery. Robust imaging response – Median functional tumor volume (FTV) measurement (performed at baseline, week 3, week 12, and at surgery) decreased 77.7 percent (range 9.0 cc → 1.2 cc) from baseline to surgery, and the longest tumor diameter from baseline to preoperative MRI was reduced by 36.8 percent. Well‑tolerated safety profile – Adverse events were predominantly Grade 1; vasomotor symptoms (hot flushes) and fatigue were most common. Only three Grade 3 events (two skin infections, one post‑procedural infection) occurred in a single patient and were deemed unrelated to study drug; no Grade 4 or Grade 5 events were reported. Pathologic Findings:No participants achieved a pathologic complete response (pCR), and residual cancer burden (RCB) classes skewed toward RCB‑II/III, indicating moderate to extensive residual disease. This result was anticipated based on earlier window‑of‑opportunity (neoadjuvant) studies that showed significant pathologic clearance typically requires higher systemic exposures to (Z)-endoxifen (> 500 ng/mL) to enable inhibition of PKCβ1 in addition to ERα. The 10 mg dose in this pilot was intentionally selected to establish tolerability and early biologic activity in the endocrine‑naïve setting; therefore, limited pCR rates at this dose are consistent with prior dose–response observations. "These results show that even at a low capsule strength (Z)‑endoxifen is bioactive, producing rapid Ki‑67 suppression and meaningful tumor shrinkage, while remaining highly tolerable. The study strengthens our scientific hypothesis that dual targeting of ERα and PKCβ1 is key to inducing a pathological response," said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. "Importantly, it paves the way for our ongoing I‑SPY 2 cohorts evaluating higher, potentially PKCβ1‑engaging doses of (Z)‑endoxifen alone and in combination with the CDK4/6 inhibitor abemaciclib, where we aim to translate early biomarker gains into deeper pathologic responses." Atossa is actively enrolling participants into an additional I‑SPY 2 cohort testing (Z)‑endoxifen at a 40 mg daily dose and in combination with abemaciclib, with and without ovarian function suppression. Top‑line data from these arms are expected beginning in 2026. About (Z)-Endoxifen(Z)-endoxifen is a highly potent Selective Estrogen Receptor Modulator (SERM) with demonstrated ability to inhibit—and potentially degrade—estrogen receptors. It has shown activity even in tumors that have developed resistance to other endocrine therapies. Beyond its anti-estrogenic properties, (Z)-endoxifen also targets protein kinase C beta 1 (PKCβ1), an oncogenic signaling protein, at clinically achievable blood levels. Importantly, (Z)-endoxifen seems to deliver comparable or superior bone-protective effects relative to tamoxifen, while exhibiting minimal or no endometrial proliferative activity—addressing key limitations of current standard-of-care therapies. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that is enteric-coated to bypass stomach acid, which would otherwise convert the active (Z)-isomer to its inactive (E)-form. This innovation ensures optimal bioavailability and therapeutic integrity. Clinical studies have shown Atossa's (Z)-endoxifen to be well tolerated in both healthy women and those with breast cancer. Atossa is prioritizing the development of (Z)-endoxifen for the treatment of metastatic breast cancer, where novel therapeutic options are urgently needed. The compound is currently being evaluated in three Phase 2 trials: one in women with ductal carcinoma in situ (DCIS) and two in women with ER+/HER2- breast cancer, including the EVANGELINE trial and the combination I-SPY study. Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including three recently issued U.S. patents and numerous pending applications worldwide. About Atossa TherapeuticsAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit FORWARD LOOKING STATEMENTSThis press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the potential indications that the Company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval, benefits of the Company's strategy of pursuing a metastatic indication for (Z)-endoxifen, the expected design and enrollment of trials and timing of data and related publications, and the potential market and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: our ability to obtain patent coverage for our product candidates; macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance or maintain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. View original content to download multimedia: SOURCE Atossa Therapeutics Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-03-2025
- Health
- Yahoo
Measles is highly contagious, experts explain how to stay protected
ELMIRA, N.Y. (WETM) — Measles cases are increasing nationwide and health officials in the Southern Tier are urging the public to take precautions. According to local health officials, the highly contagious virus affects both children and adults. Health officials say it's typically spread through the air when an infected person coughs or sneezes. Even if you don't have direct contact with someone who is sick, the virus can linger in the air for up to two hours, putting anyone nearby at risk. Infectious Disease Specialist, Justin Nistico from Arnot Health said there are symptoms of measles to look out for. 'You start seeing the telltale symptoms of either a fever, cough, runny nose and maybe this typical rash, which is usually a whole-body rash, you may even just see it in spots on the face,' said Dr. Nistico. LECOM and EOP to host free community health fair 'Measles is very contagious, it's assumed that for every one person who has measles if they were to walk into a room with unvaccinated people, that for every one person who is sick with measles, they could infect nine to 10 individuals,' said Sarah Mattison, Chemung County Deputy Public Health Director. Dr. Nistico said a rash is more common in children, and some may also experience muscle aches. He said measles can also lead to severe health complications, including brain swelling, and in some cases, even death, particularly in young children. Health officials stressed that the best way to prevent measles is through vaccination. According to Mattison, the MMR vaccine, which protects against measles, mumps, and rubella is given in a two-dose series and is highly effective. Medication disposal event available to Chemung County residents in April Dr. Nistico added children typically get the first dose around the age of one and there's a booster given at the age of four. 'Children who have been vaccinated with the MMR vaccine rarely ever develop infection with measles, children who also get the vaccine rarely have complications if they are infected with measles,' Nistico said. 'If you don't get vaccinated your risk of getting measles is quite high,' he said. Mattison said anyone born before 1957 is presumed to already have natural immunity from having been exposed to measles during their own childhood. EOP to host program to promote healthy eating in the Southern Tier There has been some discussion about other ways to combat measles, according to Dr. Nistico, including the use of Vitamin A. While it may help malnourished children have better outcomes, Dr. Nistico emphasized that it is not a cure. 'There is a lot of discussion about using Vitamin A, the data behind use of Vitamin A is in children who're malnourished,' said Dr. Nistico. 'Taking Vitamin A tends to give them nourishment and vitamins and also at the same time helps them not have as serious an outcome with measles, but it's not to say it's going to treat or cure measles. A lot of other things that are tried out just don't have any data associated with them, so the most important one is really this MMR or the measles vaccine,' he said. With measles cases on the rise across the nation, local health officials urged people to check their vaccination records and be aware of symptoms. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12-03-2025
- Politics
- Yahoo
Senator Webb awarded by SUNY for dedication to equal opportunity
ALBANY, N.Y. (WIVT/WBGH) – Senator Lea Webb was recognized as an advocate for higher education during an award ceremony over the weekend. Webb was honored with the Educational Opportunity Program (EOP) Champion Award during the 2nd Annual Alumni Reception at the New York State Association of Black, Puerto Rican, Hispanic & Asian Legislators Caucus Weekend. The award was presented by the State University of New York's Office of Opportunity Programs. Webb was given the award for her dedication to the Educational Opportunity Program. 'As a member of the Senate's Higher Education Committee, I am deeply honored to receive the EOP Champion Award, especially as an EOP alumnus,' said Webb. 'This program gave me the opportunity to succeed and it's a privilege to give back by advocating for others who are pursuing higher education. I remain committed to ensuring that all students, particularly those from underserved communities, have access to the resources and support they need to achieve their dreams.' During the event, distinguished alumni of the New York State Legislature were recognized for their contributions to higher education as they celebrated the future leaders of tomorrow. Senator Webb awarded by SUNY for dedication to equal opportunity BPD: Shots fired on West End Ave; suspect in custody Plan your wedding with help from Kilmer Mansion Suspects in Nordquist murder case plead not guilty EU retaliates as Trump steel, aluminum tariffs take effect Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
06-03-2025
- Business
- Yahoo
Here's Elon Musk's Government Email (Do With This What You Will)
The government email address of powerful unelected bureaucrat Elon Musk is now publicly available. The Intercept reports that Musk has been assigned the email address erm71@ due to his status with the White House Office and the Executive Office of the President. Erm71 refers to Musk's full initials and his 1971 birth year and is different from other email addresses in the EOP, which usually include the employee's full first and last name. The publication has already filed multiple Freedom of Information Act (FOIA) requests for Musk's emails to his pet project, the Department of Government Efficiency, as well other agencies that have worked closely with DOGE, such as the Office of Management and Budget and the Office of Personnel Management. In addition, the Intercept filed FOIA requests with several agencies in DOGE's crosshairs. The Trump administration has tried to classify DOGE, and by extension, Musk, under the EOP to claim that its administrator reports to the White House chief of staff, and therefore, White House lawyers argue, isn't subject to FOIA. The administration has also argued in court that Musk is not in charge of DOGE, but merely is a senior adviser to the president, which President Trump has repeatedly contradicted publicly. Given DOGE's massive reach within the federal government and its efforts to decimate federal agencies through mass purges of employees, its attempts at subterfuge are facing numerous legal challenges. Now that Musk's apparent government email address is public, the lawsuits from government employees and watchdog organizations trying to exact some transparency and accountability over DOGE just got some new ammunition.
